Immunic (IMUX) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Immunic (NASDAQ: IMUX) recently:

• 4/19/2026 – Immunic was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/16/2026 – Immunic was given a new $2.50 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 4/15/2026 – Immunic was downgraded by D. Boral Capital from “buy” to “hold”.
• 4/11/2026 – Immunic was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/24/2026 – Immunic is now covered by Guggenheim. They set a “buy” rating and a $7.00 price target on the stock.
• 3/2/2026 – Immunic had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a “buy” rating on the stock.

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.